Novartis stock edged higher early Wednesday, still in a buy zone, after the Swiss pharmaceutical company reported adjusted earnings of $1.32 per share on $12.4 billion in sales for its fourth quarter.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,